Stanford Cancer Institute News

Stanford Cancer Institute News is a quarterly update for members, supporters and friends. On behalf of our members and staff, we thank you for your ongoing support and welcome your feedback and inquiries.

Featured Articles from the Current Issue

How Epigenetic Factors Influence Cell Behavior

The Power of Genes

“Cancer is a disease of genes,” says SCI member Howard Chang, MD, PhD, a Professor of Dermatology in the Stanford School of Medicine. So for healthy cells to turn malignant something must go wrong with their genes, right? Not necessarily.

In Profile

Elizabeth Anderson

The Stanford Cancer Institute is pleased to welcome Elizabeth Anderson as the new Executive Administrative Director of the SCI Cancer Clinical Trials Office (CCTO).   

The CCTO provides comprehensive administrative, study management and regulatory services to SCI investigators involved in the design and conduct of cancer-related clinical trials. At any given time, the CCTO is administering hundreds of ongoing trials.

In Conversation

Fran Codispoti

Fran Codispoti has a long and intensely personal relationship with cancer treatment at Stanford. A survivor, a mother and an engaged community member, she transitioned from the world of business to the world of philanthropy, and has been a stalwart advisor and supporter for the Stanford Cancer Institute. She is a
long-serving leader on the SCI Cancer Council and an original member of the Under One Umbrella committee, which hosts an annual gala luncheon supporting the Stanford Women’s Cancer Center.

Research Advances Enable Individualized Patient Care

SCI's Clinical Breast Cancer Program

About 250,000 women are diagnosed with breast cancer each year in the US, and about 40,000 women die of the disease. While no one would suggest that any two of these women are the same, until the early 2000s their disease was considered to be one-size-fits-all.

It is now clear that breast cancer is not a single disease, but in fact a family of related diseases. The different forms of the disease—often referred to as intrinsic sub-types (based on pioneering discovery research here at Stanford using gene “chip” array technology)—feature unique genetic and behavior characteristics, as well as differing risk factors, which require more nuanced treatments strategies.

Current Issue

Past Issues


Stanford Cancer Institute
Lorry Lokey Building/SIM 1
265 Campus Drive, Suite G2103
Stanford, CA 94305